Eva B. Brittebo

Eva B. Brittebo

Auto-generated profile, based on publicly available information

Eva B. Brittebo

Department of Pharmaceutical Biosciences, Uppsala University, SE-751 24 Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2012 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
MFMoa Fransson
Moa Fransson
EPElena Piras
Elena Piras
JBJoachim Burman
Joachim Burman
BNBerith Nilsson
Berith Nilsson
MEMagnus Essand
Magnus Essand
ALAngelica Loskog
Angelica Loskog
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). In the murine experimental autoimmune encephalomyelitis (EAE) model of MS, T regulatory (Treg) cell therapy has proved to be beneficial, but generation of stable CNS-targeting Tregs needs further development. Here, we propose gene engineering to achieve CNS-targeting Tregs from naïve CD4 cells and demonstrate their efficacy in the EAE model.

1 July 2009 in Toxicology
Verified
Journal Article
Closed access
HAHelén Andersson
Helén Andersson
EPElena Piras
Elena Piras
JDJemal Demma
Jemal Demma
BHBjörn Hellman
Björn Hellman
EBEva Brittebo
Eva Brittebo

1 March 2002 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
BUBergman U.
Bergman U.
ÖAÖStergren A.
ÖStergren A.
GAGustafson A.-L.
Gustafson A.-L.
BEBrittebo E.
Brittebo E.

25 March 2009 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
OKOskar Karlsson
Oskar Karlsson
NLNils Gunnar Lindquist
Nils Gunnar Lindquist
EBEva B. Brittebo
Eva B. Brittebo
ERErika Roman
Erika Roman
Cyanobacteria are extensively distributed in terrestrial and aquatic environments all over the world. Most cyanobacteria can produce the neurotoxin β-N-methylamino-L-alanine (BMAA), which has been detected in several water systems and could accumulate in food chains. The aim of the study was to investigate the transfer of BMAA to fetal and neonatal brains and the effects of BMAA on the development of behavioral characteristics during the brain growth spurt (BGS) in rodents. Pregnant and neonatal mice were given an injection of 3H-BMAA on gestational day 14 and postnatal day (PND) 10, respectively, and processed for tape-section autoradiography. The study revealed transplacental transfer of 3H-BMAA and a significant uptake in fetal mouse brain. The radioactivity was specifically located in the hippocampus, striatum, brainstem, spinal cord and cerebellum of 10-day-old mice. The effect of repeated BMAA treatment (200 or 600 mg/kg sc) during BGS on rat behavior was also studied. BMAA treatment on PND 9–10 induced acute alterations, such as impaired locomotor ability and hyperactivity, in the behavior of neonatal rats. Furthermore, rats given the high dose of BMAA failed to habituate to the test environment when tested at juvenile age. In conclusion, the results demonstrated that BMAA was transferred to the neonatal brain and induced significant changes in the behavior of neonatal rats following administration during BGS. The observed behavioral changes suggest possible cognitive impairment. Increased information on the long-term effects of BMAA on cognitive function following fetal and neonatal exposure is required for assessment of the risk to children's health.

1 May 1990 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
IBI. Brandt
I. Brandt
EBE.B. Brittebo
E.B. Brittebo
VFV.J. Feil
V.J. Feil
JBJ.E. Bakke
J.E. Bakke

1 April 2005 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
UWUlrika Westin
Ulrika Westin
EPElena Piras
Elena Piras
BJBjörn Jansson
Björn Jansson
UBUlrika Bergström
Ulrika Bergström
MDMaria Dahlin
Maria Dahlin
EBErik Björk
Erik Björk